Answers are grounded in this paper and cite their sources.
Click to increase image sizeClick to decrease image size We would like to thank the discussants Mouna Akacha, Tianmeng Lyu, and Stijn Vansteelandt for their interesting and thoughtful comments on our paper "Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions." (Van Lancker et al., 2022 Van Lancker, K., S. Tarima, J. Bartlett, M. Bauer, B. Bharani-Dharan, F. Bretz, N. Flournoy, H. Michiels, C. Olarte Parra, J. L. Rosenberger, and S. Cro (2022). Estimands and their estimators for clinical trials impacted by the COVID-19 pandemic: a report from the NISS Ingram Olkin forum series on unplanned clinical trial disruptions. Statistics in Biopharmaceutical Research, 1–12. DOI: 10.1080/19466315.2022.2094459.[Taylor & Francis Online], [Web of Science ®] , [Google Scholar]). We also would like to extend our gratitude to Toshimitsu Hamasaki for making this a discussion article.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
No takes yet. Share an insight, caveat, or question.
Lancker et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: